PHARMAORIGIN ApS
Key figures
- Return on assets
- 0%
- Return on equity
- 6.8%
- Current ratio
- –
- Equity ratio
- 100%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | 0 |
Operating profit | 0 |
Finance income | 100,000 |
Tax expense | 0 |
Profit/loss for the year | 100,000 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 0 |
Personnel costs | 0 DKK |
Balance sheet
| Reporting period | |
|---|---|
Current assets | 1,477,000 |
Total assets | 1,477,000 |
Equity | 1,477,000 |
Liabilities | 0 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 246,000 |
Retained earnings | 1,231,000 |
Annual report highlights
Business and development
Pharmaorigin ApS is a 100% owned subsidiary of Savara ApS and part of the Savara Inc. group. Savara Inc. is a U.S.-based emerging pharmaceutical development company. The Company is focused on advancing inhalation therapies for the treatment of patients with rare pulmonary conditions.
Pharmaorigin ApS has one development study, F7. There has been no development activities in Pharmaorigin ApS since the Company was bought by Savara Inc. in 2016.
Financial review
The company's income statement for the year ended 31 December 2025 shows a profit of kDKK 100, and the balance sheet at 31 December 2025 shows equity of kDKK 1.477.
FinancingBased on a letter of support from the parent company Savara Inc., Pharmaorigin ApS has a satisfactory funding assurance until the end of 2026 to continue the operation of the Company as planned. Hence, the annual report for 2025 has been prepared for on-going business.
Risks and material matters
Based on a letter of support from the parent company Savara Inc., Pharmaorigin ApS has a satisfactory funding assurance until the end of 2026 to continue the operation of the Company as planned.
No events have occurred after the balance sheet date which could significantly affect the Company's financial position.
Commitments and security
The Company is jointly taxed with the other Danish companies in the group and has joint, several and unlimited liability for income taxes for the jointly taxed companies. The liability also includes any subsequent corrections to the calculated tax liability as a consequence of changes made to the jointly taxable income etc.
Other contingent liabilities not recognised in balance sheetThe Company has no contingent liabilities.
Create a free account to see up to 9 years of financial history
Create free account